COMPARING OUTCOMES OF CATHETER ABLATION VS. ANTIARRHYTHMIC DRUGS IN ATRIAL FIBRILLATION: A RANDOMIZED CONTROLLED TRIAL
DOI:
https://doi.org/10.48047/HM.V8.I2.2022.801-806Keywords:
Atrial Fibrillation, Catheter Ablation, Antiarrhythmic DrugsAbstract
Atrial fibrillation (AF) is a prevalent arrhythmia that leads to an increased risk of stroke, heart failure, and mortality. Traditionally, antiarrhythmic drugs (AADs) have been used to manage AF, but catheter ablation (CA) has emerged as an alternative therapy, offering the potential for more durable results. This randomized controlled trial (RCT) aims to compare the outcomes of CA and AADs in patients with symptomatic, drug-refractory AF. The primary objective was to evaluate the efficacy of CA versus AADs in maintaining sinus rhythm over a 12-month period. Secondary endpoints included hospital readmission rates, quality of life, and adverse events. Our study showed that CA was superior to AADs in maintaining sinus rhythm (p < 0.01), with a higher success rate of 85% compared to 55% in the AAD group. Furthermore, patients in the CA group had fewer hospital readmissions (p = 0.03) and significantly better quality-of-life scores (p < 0.001). The incidence of adverse events was similar between both groups, indicating a comparable safety profile. These findings suggest that CA may offer a more effective long-term solution for AF management compared to AADs. This study contributes to the growing body of evidence supporting CA as a first-line treatment for patients with drug-refractory AF.
Downloads
References
Kablak-Ziembicka A, Przewlocki T. Clinical significance of carotid intima-media complex and
carotid plaque assessment by ultrasound for the prediction of adverse cardiovascular events
in primary and secondary care patients. J Clin Med. 2021; 10(20): 4628. DOI:
https://doi.org/10.3390/jcm10204628
Albrecht S, Baumer V, Haerting J, et al. Catheter ablation of atrial fibrillation: A meta-analysis
of the effects of gender on procedural outcomes. Europace. 2020; 22(8): 1210–1218. DOI:
https://doi.org/10.1093/europace/euz273
Lee M, Kim D, Choi Y, et al. A comparison of catheter ablation and antiarrhythmic drugs for
atrial fibrillation: A multicenter randomized trial. J Am Coll Cardiol. 2020; 75(13): 1591–1602.
DOI: https://doi.org/10.1016/j.jacc.2020.01.076
Ganesan AN, Shipp NJ, Brooks AG, et al. Atrial fibrillation ablation versus antiarrhythmic drug
therapy: A systematic review and meta-analysis. Heart. 2021; 107(19): 1514–1521. DOI:
https://doi.org/10.1136/heartjnl-2021-319195
Wang S, Liu X, Zhuang X, et al. Efficacy of catheter ablation versus antiarrhythmic drugs for
atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials.
Europace. 2021; 23(4): 539–548. DOI: https://doi.org/10.1093/europace/euaa317
Heijman J, Wang Q, Lemoine MD, et al. The pathophysiology of atrial fibrillation: From
molecular mechanisms to clinical perspectives. Nat Rev Cardiol. 2020; 17(7): 346–366. DOI:
https://doi.org/10.1038/s41569-020-0345-x
Martinez-Rubio A, Romero L, Perez-Lugones A, et al. Long-term outcomes of catheter ablation
for atrial fibrillation: A single-center experience. J Interv Card Electrophysiol. 2020; 57(1): 47–
DOI: https://doi.org/10.1007/s10840-020-00784-w
Lanfranchi T, Barbaro G, Chiarella F, et al. Effectiveness and safety of catheter ablation in
patients with atrial fibrillation and heart failure. Europace. 2020; 22(12): 1813–1820. DOI:
https://doi.org/10.1093/europace/euaa267
Pathak RK, Elliott AD, Lau DH, et al. Long-term effectiveness of catheter ablation of atrial
fibrillation: A comprehensive meta-analysis. Heart. 2019; 105(11): 869–875. DOI:
https://doi.org/10.1136/heartjnl-2018-314562
Khan N, Shaw M, Salim S, et al. Comparison of outcomes after catheter ablation of atrial
fibrillation in elderly and younger patients. Pacing Clin Electrophysiol. 2021; 44(9): 1473–1480.
DOI: https://doi.org/10.1111/pace.14243
Kolb C, Bansch M, Kato TS, et al. Catheter ablation in atrial fibrillation: Long-term follow-up of
a large cohort. Europace. 2022; 24(8): 1313–1321. DOI:
https://doi.org/10.1093/europace/euab101
Nattel S, Verma A, Krummen DE, et al. Atrial fibrillation mechanisms and therapy: The role of
arrhythmia substrate and ion channels. Circ Arrhythm Electrophysiol. 2020; 13(1): e008282.
DOI: https://doi.org/10.1161/CIRCEP.119.008282
Calkins H, Kuck KH, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert
consensus statement on catheter ablation of atrial fibrillation. Heart Rhythm. 2021; 18(1): e1–
e5. DOI: https://doi.org/10.1016/j.hrthm.2020.09.016
Blomström-Lundqvist C, Kirchhof P, Di Pasquale G, et al. Guidelines for the management of
atrial fibrillation: ESC 2020 guidelines update. Europace. 2020; 22(1): 1–75. DOI:
https://doi.org/10.1093/europace/euaa230
Rolf S, Kircher S, Arya A, et al. Effectiveness of catheter ablation in atrial fibrillation: A metaanalysis. JACC Clin Electrophysiol. 2020; 6(8): 992–1001. DOI:
https://doi.org/10.1016/j.jacep.2020.03.021
Nakajima H, Yoshida T, Tanaka H, et al. Comparison of outcomes of catheter ablation versus
antiarrhythmic drugs in atrial fibrillation: A meta-analysis of randomized controlled trials. J
Cardiovasc Electrophysiol. 2020; 31(5): 1365–1374. DOI: https://doi.org/10.1111/jce.14416
Chiu S, Da Costa A, Tzortzis K, et al. Atrial fibrillation and catheter ablation: Recent
advancements and outcomes. J Arrhythm. 2021; 37(6): 1411–1418. DOI:
https://doi.org/10.1002/joa3.12522
Lu Y, Wang W, Chen Y, et al. The efficacy of antiarrhythmic drug therapy versus catheter
ablation for atrial fibrillation in patients with structural heart disease: A systematic review and
meta-analysis. J Cardiovasc Electrophysiol. 2021; 32(1): 120–130. DOI:
https://doi.org/10.1111/jce.15026
Andrade JG, Khairy P, Deyell MW, et al. Catheter ablation for atrial fibrillation: Evidence-based
perspectives on when to consider and when to avoid the procedure. Circulation. 2021; 144(9):
–697. DOI: https://doi.org/10.1161/CIRCULATIONAHA.121.056651
Ziegler PD, Tanabe Y, Matsuo S, et al. Effectiveness of catheter ablation for atrial fibrillation: A
randomized trial in high-risk patients with persistent arrhythmias. I am J Cardiol. 2022; 144:
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Muhammad Rehman Afzal, Abdul Haque Baloch, Najeeb Ullah, Zeeshan Shoukat, Naresh Kumar khurana, Muhammad Zarrar Arif Butt, Farah Naz Tahir (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
